Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Reaxense aids in their synthesis and provision.


The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.


We use our state-of-the-art dedicated workflow for designing focused libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
Q6FHJ7

UPID:
SFRP4_HUMAN

ALTERNATIVE NAMES:
Frizzled protein, human endometrium

ALTERNATIVE UPACC:
Q6FHJ7; B4DYC1; O14877; Q05BG7; Q1ZYW2; Q4G124; Q6FHM0; Q6PD64

BACKGROUND:
SFRP4, identified for its phosphaturic effects, is a key player in Wnt signaling pathways, affecting cell differentiation and growth. Its role extends to adult uterine morphology and function, and it may influence apoptosis during ovulation. The protein's alternative name, Frizzled protein, human endometrium, reflects its tissue-specific expression.

THERAPEUTIC SIGNIFICANCE:
Understanding the role of Secreted frizzled-related protein 4 could open doors to potential therapeutic strategies. Its involvement in diseases like Pyle disease presents a unique opportunity for developing targeted therapies to improve bone health and treat skeletal abnormalities.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.